And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our own agenda is somewhat promising. We hope to hang with one or more short people, catch up on our reading, and touch base with a like-minded conspirator from our past. And what about you? Spring is closing in quickly, so this may be a good time to get a head start on cleaning out your castle or taking in the great outdoors. You could count your blessings that you got your college degree the old-fashioned way — you earned it. Or maybe simply make time for someone special. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …

A debate over the use of list prices to gauge the rising cost of medicines broke out in the Health Affairs blog. Robert DuBois of the National Pharmaceutical Council criticized a recent paper by arguing that “the use of list price leads to misleading results” because these do not reflect rebates paid by drug makers to win favorable insurance coverage. But the authors of that paper countered that it would be “problematic” to withhold research based on list prices because uninsured and underinsured patients are exposed to list prices.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • This quote from Purdue bemuses me – “will not profit from nalmefene HCI.” And so they will seque to being a ‘not for profit’ company? Am I alone in find this … bemusing? (Or odd / confusing, if you prefer …)

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy